The BioNTech SE ADR BNTX inched 0.69% higher to $113.05 Monday, on what proved to be an all-around positive trading session ...
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
Investor's Business Daily on MSN7d
How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A RecoveryBioNTech stock has climbed 25% over four days as the German biotech rides a round of cancer treatment success from Summit ...
Discover BioNTech SE's innovative RNA lipoplex patent, detailing advanced methods for stable RNA delivery, GMP production, and effective intravenous administration.
BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.
The BioNTech SE ADR BNTX shed 0.20% to $112.28 Friday, on what proved to be an all-around mixed trading session for the stock ...
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a ...
BioNTech BNTX has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from ...
The NHS is offering autumn Covid boosters to the most vulnerable in October. Many pharmacies also now sell the Covid jab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback